Safety and Tolerability of Glatiramer Acetate (GLACIER)

Study Title
Safety and Tolerability of Glatiramer Acetate
Teva Identifier
GA-MS-303
ClinicalTrials.gov Identifier
NCT01874145
Study Status
Completed
Trial Condition(s)
Relapsing-Remitting Multiple Sclerosis
Interventions
Drug: GA 20 mg/mL | Drug: GA 40 mg/mL

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
18 Years and older
Trial Duration
06/01/2013 - 05/01/2014
Phase
Phase 3

Study Type

Interventional